Membrane-bound p35 Subunit of IL-12 on Tumor Cells is Functionally Equivalent to Membrane-bound Heterodimeric Single Chain IL-12 for Induction of Anti-tumor Immunity
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
In this study, we compared two different tumor cell vaccines for their induction of anti-tumor immunity; one was a tumor cell clone expressing a membrane-bound form of IL-12 p35 subunit (mbIL-12 p35 tumor clone), and the other was a tumor clone expressing heterodimeric IL-12 as a single chain (mb-scIL-12 tumor clone). The stimulatory effect of mb-scIL-12 on the proliferation of ConA-activated splenocytes was higher than that of mbIL-12 p35 in vitro . However, the stimulatory effect of mbIL-12 p35 was equivalent to that of recombinant soluble IL-12 (3 ng/ ml). Interestingly, both tumor clones (mbIL-12 p35 and mb-scIL-12) showed similar tumorigenicity and induction of systemic anti-tumor immunity in vivo, suggesting that tumor cell expression of the membrane-bound p35 subunit is sufficient to induce anti-tumor immunity in our tumor vaccine model.
Abstract
In this study, we compared two different tumor cell vaccines for their induction of anti-tumor immunity; one was a tumor cell clone expressing a membrane-bound form of IL-12 p35 subunit (mbIL-12 p35 tumor clone), and the other was a tumor clone expressing heterodimeric IL-12 as a single chain (mb-scIL-12 tumor clone). The stimulatory effect of mb-scIL-12 on the proliferation of ConA-activated splenocytes was higher than that of mbIL-12 p35 in vitro . However, the stimulatory effect of mbIL-12 p35 was equivalent to that of recombinant soluble IL-12 (3 ng/ ml). Interestingly, both tumor clones (mbIL-12 p35 and mb-scIL-12) showed similar tumorigenicity and induction of systemic anti-tumor immunity in vivo, suggesting that tumor cell expression of the membrane-bound p35 subunit is sufficient to induce anti-tumor immunity in our tumor vaccine model.
참고문헌 (24)
- Schoenhaut, D. S., "Cloning and expression of murine IL-12", J. Immunol, 148, pp.3433~3440 (1992)
- Trinchieri, G, "Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes", Blood, 84, pp.4008~4027 (1994)
- Hsieh, C. S, "Development of TH1CD4+ T cells through IL-12 produced by Listeria-induced macrophages", Science, 260, pp.547~549 (1993)
- Gately, M. K, "Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-gamma in vivo", Int. Immunol, 6, pp.157~167 (1994)
- Hendrzak, J. A, "Antitumor and antimetastatic activity of interleukin-12", Curr. Top. Microbiol. Immunol, 213, pp.65~83 (1996)
- Nastala, C. L, "Recombinant IL-12administration induces tumor regression in association with IFN-gamma production", J. Immunol, 153, pp.1697~1706 (1994)
- Brunda, M. J, "Antitumor and antimetastatic activity of interleukin 12 against murine tumors", J. Exp. Med, 178, pp.1223~1230 (1993)
- Leonard, J. P, "Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production", Blood, 90, pp.2541~2548 (1997)
- Atkins, M. B, "Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies", Clin. Cancer Res, 3, pp.409~417 (1997)
- Car, B. D, "The toxicology of interleukin-12: a review", Toxicol. Pathol, 27, pp.58~63 (1999)
- Mach, N, "Cytokine-secreting tumor cell vaccines", Curr. Opin. Immunol, 12, pp.571~575 (2000)
- Chang, C. J, "The immunization site of cytokine-secreting tumor cell vaccines influences the trafficking of tumor-specific T lymphocytes and antitumor efficacy against regional tumors", J. Immunol, 173, pp.6025~6032 (2004)
- Ji, J, "Synergistic anti-tumor effect of glycosylphosphatidylinositol-anchored IL-2 and IL-12", J. Gene Med, 6, pp.777~785 (2004)
- Tahara, H, "Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer", Gene Ther, 2, pp.96~106 (1995)
- Kim, Y. S, "Tumor cells expressing membrane-bound form of IL-4 induce antitumor immunity", Gene Ther, 7, pp.837~843 (2000)
- 장미라, "Antitumor immunity induced by tumor cells engineered to express a membrane-bound form of IL-2", Experimental and Molecular Medicine, 37(3), pp.240~249 (2005), 생화학분자생물학회
- Lim, H. Y, "Antitumor effects of a tumor cell vaccine expressing a membrane-bound form of the IL-12 p35 subunit", Cancer Biol. Ther, 10, pp.336~343 (2010)
- 임호영, "Tumor Cell Clone Expressing the Membrane-bound Form of IL-12p35 Subunit Stimulates Antitumor Immune Responses Dominated by CD8＋ T Cells", Immune Network, 13(2), pp.63~69 (2013), 대한면역학회[DOI]
- D'Andrea, A, "Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells", J. Exp. Med, 176, pp.1387~1398 (1992)
- Podlaski, F. J, "Molecular characterization of interleukin 12", Arch. Biochem. Biophys, 294, pp.230~237 (1992)
- Pan, W. Y., "Cancer immunotherapy using a membrane-bound interleukin-12 with B7-1 transmembrane and cytoplasmic domains", Mol. Ther, 20, pp.927~937 (2012)
- Lode, H. N, "Gene therapy with a single chain interleukin 12 fusion protein induces T cell-dependent protective immunity in a syngeneic model of murine neuroblastoma", Proc. Natl. Acad. Sci. U. S. A, 95, pp.2475~2480 (1998)
- Collison, L. W, "The inhibitory cytokine IL-35 contributes to regulatory T-cell function", Nature, 450, pp.566~569 (2007)
- Wang, Z, "Tumor-derived IL-35 promotes tumor growth by enhancing myeloid cell accumulation and angiogenesis", J. Immunol, 190, pp.2415~2423 (2013)